181 related articles for article (PubMed ID: 32523042)
21. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
22. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
23. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
24. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo.
Tao J; Zhang M; Wen Z; Wang B; Zhang L; Ou Y; Tang X; Yu X; Jiang Q
Biomed Pharmacother; 2018 Oct; 106():1727-1733. PubMed ID: 30119248
[TBL] [Abstract][Full Text] [Related]
26. Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
Bemanian V; Noone JC; Sauer T; Touma J; Vetvik K; Søderberg-Naucler C; Lindstrøm JC; Bukholm IR; Kristensen VN; Geisler J
Breast Cancer Res Treat; 2018 Nov; 172(2):339-351. PubMed ID: 30132219
[TBL] [Abstract][Full Text] [Related]
27. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
28. Correlate the
Lyu H; Li M; Jiang Z; Liu Z; Wang X
Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295
[TBL] [Abstract][Full Text] [Related]
29. Mutations truncating the EP300 acetylase in human cancers.
Gayther SA; Batley SJ; Linger L; Bannister A; Thorpe K; Chin SF; Daigo Y; Russell P; Wilson A; Sowter HM; Delhanty JD; Ponder BA; Kouzarides T; Caldas C
Nat Genet; 2000 Mar; 24(3):300-3. PubMed ID: 10700188
[TBL] [Abstract][Full Text] [Related]
30. Immune-related genes have prognostic significance in head and neck squamous cell carcinoma.
Yang J; Xie K; Li C
Life Sci; 2020 Sep; 256():117906. PubMed ID: 32504750
[TBL] [Abstract][Full Text] [Related]
31. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Grivas P; Mortazavi A; Picus J; Hahn NM; Milowsky MI; Hart LL; Alva A; Bellmunt J; Pal SK; Bambury RM; O'Donnell PH; Gupta S; Guancial EA; Sonpavde GP; Faltaos D; Potvin D; Christensen JG; Chao RC; Rosenberg JE
Cancer; 2019 Feb; 125(4):533-540. PubMed ID: 30570744
[TBL] [Abstract][Full Text] [Related]
32. Virtual screening of mutations in antioxidant genes and its putative association with HNSCC: An in silico approach.
J VP; A P
Mutat Res; 2020; 821():111710. PubMed ID: 32593872
[TBL] [Abstract][Full Text] [Related]
33. Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas.
Ma B; Li H; Qiao J; Meng T; Yu R
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111959
[TBL] [Abstract][Full Text] [Related]
34. Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.
Luo M; Zhang Y; Xu Z; Lv S; Wei Q; Dang Q
Mol Med; 2023 Jan; 29(1):7. PubMed ID: 36647005
[TBL] [Abstract][Full Text] [Related]
35. Chemical and genetic rescue of an ep300 knockdown model for Rubinstein Taybi Syndrome in zebrafish.
Babu A; Kamaraj M; Basu M; Mukherjee D; Kapoor S; Ranjan S; Swamy MM; Kaypee S; Scaria V; Kundu TK; Sachidanandan C
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1203-1215. PubMed ID: 29409755
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ
BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811
[TBL] [Abstract][Full Text] [Related]
37. miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells.
Vahabi M; Pulito C; Sacconi A; Donzelli S; D'Andrea M; Manciocco V; Pellini R; Paci P; Sanguineti G; Strigari L; Spriano G; Muti P; Pandolfi PP; Strano S; Safarian S; Ganci F; Blandino G
J Exp Clin Cancer Res; 2019 Mar; 38(1):141. PubMed ID: 30925916
[TBL] [Abstract][Full Text] [Related]
38. Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions.
Carenzo A; Serafini MS; Roca E; Paderno A; Mattavelli D; Romani C; Saintigny P; Koljenović S; Licitra L; De Cecco L; Bossi P
Cells; 2020 Aug; 9(8):. PubMed ID: 32756466
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
40. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
